Anavex Life Sciences Corp (AVXL)

[nidan7500]

In the Core study, the overall rate of amyloid-related imaging abnormalities-edema/effusion (ARIA-E), an adverse event associated with anti-amyloid beta antibodies therapies was 9.9% (16/161) of patients treated with lecanemab 10 mg/kg biweekly compared with 0.8% (2/245) of placebo patients. The results from Study 201 were published in a peer-reviewed journal Alzheimer’s Research and Therapy in April 2021.

https://investors.biogen.com/news-releases/news-release-details/eisai-completes-rolling-submission-us-fda-biologics-license